Milestone Pharmaceuticals starts pivotal Phase 3 trial of etripamil nasal spray
Milestone Pharmaceuticals initiated a pivotal Phase 3 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.